Cart
sales@molnova.com
6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide
CAS No. 342417-01-0
6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide ( —— )
Catalog No. M28871 CAS No. 342417-01-0
6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide can be used in the synthesis of befetupitant and netupitant.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 45 | Get Quote |
|
| 10MG | 68 | Get Quote |
|
| 25MG | 115 | Get Quote |
|
| 50MG | 173 | Get Quote |
|
| 100MG | 258 | Get Quote |
|
| 200MG | 388 | Get Quote |
|
| 500MG | 642 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide
-
NoteResearch use only, not for human use.
-
Brief Description6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide can be used in the synthesis of befetupitant and netupitant.
-
Description6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide can be used in the synthesis of befetupitant and netupitant.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorCCR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number342417-01-0
-
Formula Weight310.4
-
Molecular FormulaC18H22N4O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCN1CCN(CC1)c1cc(c(cn1)C(N)=O)-c1ccccc1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Maria Grazia Martina, et al. Discovery of small-molecules targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases. Eur J Med Chem. 2022 Aug 29;243:114703.
molnova catalog
related products
-
Phthalic Acid Monooc...
Used as pharmaceutical intermediates.
-
Ethamivan
Etamivan (INN) or ethamivan (USAN), trade name Analepticon, is a respiratory stimulant drug related to nikethamide.
-
3,4,5-Tricaffeoylqui...
3,4,5-Tricaffeoylquinic acid may attenuate the TNF-α±- and LPS-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor 4 expression-mediated activation of the Akt, ERK and NF-κB pathways, it may exert an inhibitory effect against the pro-inflammatory mediator-induced skin disease.
